Exercise training for patients with heart failure (HF) has been shown to improve cardiovascular function, functional capacity, and quality of life. [1] [2] [3] Although the role of comorbid OSA has not been assessed, OSA is highly prevalent in patients with HF, 4, 5 and exercise ameliorates OSA. [6] [7] [8] [9] In the current preliminary study, we hypothesized that exercise could improve the quality of life for patients with HF through attenuation of OSA.
In this prospective study, patients who had HF with reduced ejection fraction (HFrEF) and comorbid OSA were randomized into 4 study arms, including a control group. We compared the effects of exercise training, CPAP treatment, and a combination of both interventions on cardiopulmonary performance, muscle strength and endurance, excessive daytime sleepiness, quality of life, and sexual function. The preliminary data were published in an abstract at the 29th Annual Meeting of the Associated Professional Sleep Societies. 10 
Patients and Methods

Patients
Consecutive patients who regularly attended the specialist HF center of the Federal University of São Paulo were prospectively evaluated. All patients were evaluated by the same medical staff, and the diagnosis was based on the presence of symptoms and signs of HF in combination with objective evidence of left ventricular systolic dysfunction (ejection fraction < 40%).
The inclusion criteria were as follows: age range 30 to 70 years, New York Heart Association (NYHA) 11 functional class II to III, clinically stable for 3 months with optimized medical therapy, and an ejection fraction < 40% determined by using echocardiography.
A total of 106 consecutive eligible patients underwent polysomnography, and 70 subjects met the polysomnographic criteria for OSA and were enrolled. The criteria for OSA was an apnea-hypopnea index (AHI) $ 5 events per hour with symptoms or an AHI $ 15 events per hour. 12 The exclusion criteria were as follows: NYHA functional class IV, a history of acute myocardial infarction, cardiac surgery, percutaneous coronary intervention, automatic implantable cardiac defibrillator or cardiac resynchronization therapy within the previous 4 months, unstable angina, complex or symptomatic ventricular arrhythmias, mitral or aortic stenosis, hypertrophic cardiomyopathy, abnormal exercise test results, pulmonary artery systolic pressure $ 50 mm Hg, COPD, musculoskeletal disorders, or psychiatric diseases.
Study Design
Patients were randomized (by drawing cards) into four study groups: control, exercise, CPAP, and exercise þ CPAP.
Measurement of cardiopulmonary exercise testing, muscle strength and endurance testing, subjective daytime sleepiness, quality of life, and sexual function were obtained at baseline and after 3 months of the intervention. Patients were advised to take their medication as usual, and all prescriptions remained unchanged during the 3-month study period.
The Joint Research Ethics Board of the Universidade Federal de São Paulo approved this protocol (CEP 1226/11), and the protocol is registered with ClinicalTrials.gov. 13 Informed consent was obtained from all patients.
Procedures and Outcome Measures
Questionnaires: Sleepiness was measured by using the Portuguese validated version of the Epworth Sleepiness Scale.
14 It is composed of eight situations rated on a scale of 0 to 3, with a total score > 10 indicating higher daytime sleepiness.
Quality of life was measured by using the Portuguese validated version of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) 15 and the 36-item Medical Outcomes Study Short Form Survey (SF-36). 16 The MLHFQ is used to assess the patient's perception of the effects of HF and its treatment on daily life. It comprises 21 items that measure physical, socioeconomic, and psychological impairment related to HF. Higher scores represent a lower quality of life. The SF-36 consists of 36 questions and standardized response choices that measure physical functioning, social functioning, role limitations due to physical health problems and emotional problems, mental health, vitality, bodily pain, and general health perceptions. The raw item scale scores are recorded and linearly converted to a 0-to 100-point scale, with higher scores indicating a higher quality of life.
Sexual function was evaluated by using the Sexual Quotient-Male Version 17 and Sexual Quotient-Female Version. 18 Each comprises 10 questions scored on a scale from 0 to 5. The total score was multiplied by two, resulting in a score of 0 to 100. Improved sexual function is reflected in a higher score.
Polysomnography: A full-night attended polysomnography was performed in the sleep laboratory of the Instituto do Sono de Sao Paulo and was supervised by trained professionals using a digital system (EMBLA S7000, Embla Systems, Inc) during the subject's habitual sleep time. We monitored EEG (three channels), electrooculogram (left and right eye), electromyogram (submental and anterior tibialis muscles), electrocardiogram, oronasal airflow (pressure transducer and a thermistor), thoracoabdominal excursions (inductance plethysmography), snoring, body position (sensor), oxyhemoglobin saturation (pulse oximetry), and pulse rate.
All polysomnograms were scored blindly by the same experienced sleep technician and reviewed by a sleep medicine physician. These professionals did not know to whom the examination materials belonged or which group they were in. Apneas were defined as a $ 90% reduction in airflow lasting for $ 10 s. Apneas were classified as central in the absence of thoracoabdominal excursions. Hypopneas were defined as a $ 30% reduction in airflow lasting $ 10 s, associated with a $ 4% desaturation. 19 Hypopneas were classified as obstructive if there was snoring, airflow limitation on the nasal pressure tracing, or out-of-phase thoracoabdominal motion. 20 Cardiopulmonary Exercise Testing: All patients underwent a symptom-limited treadmill test with respiratory gas exchange analysis at the Sleep Institute fitness center, according to the Weber protocol. 21 All tests were performed under the supervision of an experienced sports physician not involved in the study.
The gas exchange data were collected in a breath-by-breath manner and averaged into 30-s time periods (COSMED). BP was determined at rest and at the end of each stage by using a mercury sphygmomanometer (Oxygel). The participants were encouraged to chestjournal.org exercise until exhaustion. The self-perceived level of exertion (15-point Borg scale) 22 was assessed at peak effort. The peak oxygen consumption (peak VO 2 ) was calculated as the highest 30-s time period. VO 2 anaerobic threshold was measured by using the V-slope method. 23 The slope relating ventilation to CO 2 production (VE/ VCO 2 slope) was calculated by linear regression, excluding the nonlinear part of the data after the onset of ventilatory compensation for metabolic acidosis. 24 Isokinetic Strength and Endurance: The strength and endurance of both knee extensors and flexors were measured by using an isokinetic dynamometer (Biodex Medical Systems, Inc) at the same fitness center. All tests were performed under the supervision of experienced physiotherapists not involved in the study.
The test protocol consisted of a warm-up (5 min on a cycle ergometer), three repetitions at 60 /second and 10 repetitions at 180 /second, followed by a cool-down (5 min on a cycle ergometer). A resting phase of 3 min between the different velocities was applied. The procedure always started with a trial of the nondominant leg at submaximal level. Maximal dynamic strength (peak torque [Newton meters]) and endurance (total work [Joules]) were determined in each leg separately. The results were corrected for the weight and length of the leg. The patients were verbally encouraged to maximal effort. The following variables were recorded before and after the test: heart rate (Polar FS1), BP (mercury sphygmomanometer; Oxygel), arterial oxyhemoglobin saturation (Nonin 9500), and selfperceived level of exertion (15-point Borg scale).
Exercise Training Protocol: Exercise training for groups 2 and 4 was conducted in the fitness center of the Sleep Institute and consisted of three sessions per week on nonconsecutive days for 3 months. The sessions were supervised by a physiotherapist and a cardiologist. The protocol consisted of a warm-up period of 10 min followed by aerobic training (treadmill and cycloergometer; 30 min in the first month and 45 min in the last 2 months) and strength training (three exercises for upper limbs and four exercises for lower limbs, with a 1-min rest period, with free weights).
The aerobic exercise intensity was established by using heart rate levels that corresponded to an anaerobic threshold (VO 2 anaerobic threshold), 10 heart rates down and 10 heart rates up of this threshold, assessed according to cardiopulmonary exercise testing and controlled by a frequency meter (Polar FS1).
The strength exercise intensity was determined by 50% to 60% of the one-repetition maximum for elbow and knee extension/flexion, and the exercise progression was accomplished by either increasing the resistance (heavier free weight) or the number of repetitions (12 repetitions in the first month, 14 repetitions in the second month and 16 repetitions in the third month) for all exercises. 25 BP was measured prior to and following each supervised session. The Borg exertion scale was used to evaluate the training intensity. The first 10 min of the sessions were devoted to education regarding exercise and HF risk factors.
CPAP Treatment: Patients in groups 3 and 4 underwent CPAP titration during full night attended polysomnography at the Sleep Institute. Pressure was progressively increased to eliminate disordered breathing events. While on CPAP, AHI decreased significantly from 32 AE 25 events per hour to 6 AE 7 events per hour in group 3 and from 25 AE 15 events per hour to 7 AE 10 events per hour in group 4. Patients were discharged at a fixed pressure (Resmed S8 Scape). A physiotherapist from the CPAP Clinic of the Sleep Institute performed follow-up of all patients at 1 week, 1 month, and 3 months following the start of the treatment to encourage CPAP adherence and intervene if necessary. Adherence was monitored by using a CPAP pressure-time meter.
Control Group
The patients in the control group were also followed up at 1 week, 1 month, and 3 months. At the end of the study period, they received educational sessions about the importance of exercise training and the treatment of OSA.
Statistical Analyses
For quantitative variables, multivariate ANOVA with a Bonferroni post hoc test were used to compare the four groups. For categorical variables, the c 2 or Fisher exact test was used as appropriate. Mean AE SD and 95% CIs are reported. Statistical analyses were performed by using SPSS version 19.0 (IBM SPSS Statistics, IBM Corporation), and P values < .05 were considered statistically significant.
Results
Seventy of the 106 consecutive eligible patients met the study criteria and were randomized into the following study groups: control group (n ¼ 19), exercise group (n ¼ 18), CPAP group (n ¼ 16), and exercise þ CPAP group (n ¼ 17). Of the 70 patients, 65 (93%) completed the protocol with the following dropouts: control group, one decompensated HF; exercise group, one decompensated HF; CPAP group, one did not tolerate CPAP; and exercise þ CPAP group, one decompensated HF and one moved to another city (Fig 1) . The method of intention-to-treat last-observation-carried-forward was used to verify if the dropouts had an effect on the results, and no difference was observed.
There were no significant differences in sex, age, BMI, ejection fraction, HF etiology, NYHA functional class, medications, or baseline polysomnographic parameters among the four groups. All patients were taking a beta-blocker, and most were obese (Tables 1  and 2 ). There were no changes in medication during the study.
Six patients in the control group and two to three patients in the remaining three groups had stable Chagas disease, an infectious disease common in South America, as the cause of HF. One patient with breast cancer had had chemotherapy with liposomal doxorubicin-induced HF and had been clinically stable for 6 months.
During the study period, the weight of the participants in three groups did not change significantly: control group, 78 AE 10 kg to 78 AE 10 kg [P 
Sleep Parameters
The mean AHI did not change significantly (in events per hour of sleep) in the control group (29 AE 17 to 31 AE 14), decreased significantly in the exercise group (28 AE 17 to 18 AE 12; P < .03), and decreased even more significantly in the CPAP group (32 AE 25 to 8 AE 11; P < .007) and in the exercise þ PAP group (25 AE 15 to 10 AE 16; P < .007). This decrease in AHI was due to a reduction in obstructive apneas and hypopneas (Table 2) . We acknowledge the difficulty of accurately distinguishing obstructive from central hypopneas; however, combining all the hypopneas together does not change the results.
In concert with changes in AHI, the arousals index decreased significantly in the exercise, CPAP, and exercise þ CPAP groups, whereas it increased in the control group (P < .05) ( Table 2 ). All interventions improved sleep-related desaturation compared with the control group (P < .01). CPAP adherence was similar between the CPAP and exercise þ CPAP groups. During the study period, the percentage of nights the device was used by the CPAP and the exercise þ CPAP groups (83 AE 15% and 83 AE 15%, respectively; P ¼ .979), average use per day (5 AE 2 per hour and 4 AE 1 per hour; P ¼ .410), and percentage of days with use $ 4 h (65 AE 24% and 60 AE 26%; P ¼ .545) were not significantly different. The therapeutic pressure in the CPAP and exercise þ CPAP groups was also similar at baseline (8 AE 2 cm H 2 O and 8 AE 2 cm H 2 O; P ¼ .621) and at 3 months (9 AE 2 cm H 2 O and 8 AE 2 cm H 2 O; P ¼ .355).
Cardiopulmonary Exercise Testing
After 3 months, maximum heart rate and peak VO 2 increased, whereas VE/VCO 2 slope decreased in the exercise and exercise þ CPAP groups compared with the control and CPAP groups (P < .01, P < .01, and P < .05, respectively) ( Table 3) .
Muscle Strength and Endurance
After 3 months, muscle strength and endurance improved significantly in the exercise and exercise þ CPAP groups compared with the control group (Fig 2) .
NYHA Class, Sleepiness, Quality of Life and Sexual Function
There were no significant changes in NYHA functional class distribution, excessive daytime sleepiness, quality of life, or sexual function in the control group. In the remaining groups, a considerable proportion of patients in NYHA functional classes II and III moved into class I (P < .05). Subjective daytime sleepiness improved with Exercise n = 17 chestjournal.org all interventions (P < .05). Similarly, quality of life improved with all interventions, but compared with the control group, improvements in the MLHFQ and SF-36 were significant only in the exercise and exercise þ CPAP groups (P < .05).
In the exercise þ CPAP group, sexual function improved compared with baseline but with no difference in comparisons among groups (Table 4) .
Discussion
This randomized, parallel trial with a control group and three treatment arms showed that the mean AHI did not change significantly in the control group, decreased moderately in the exercise group, and decreased significantly in the CPAP and exercise þ CPAP groups. Both exercise and CPAP improved subjective excessive daytime sleepiness, quality of life, and the NYHA functional class distribution. However, compared with the control group, changes in the SF-36 and MLHFQ were significant only in the exercise groups. Furthermore, peak oxygen consumption, muscle strength, and endurance improved only in the exercise groups compared with the CPAP group. Interestingly, there was a trend in improved sexual function when exercise was combined with CPAP. Exercise could have decreased AHI by a variety of mechanisms such as through decreasing lower extremity edema and consequent cephalad fluid translocation in the supine positon, 26 or decreased body weight, although the reduction was small.
These findings have important implications in the management of patients with HF and OSA. The data suggest that exercise could be a therapeutic option for patients with HF and OSA who refuse CPAP or are intolerant to it. In this regard, a considerable number of patients with HF and OSA do not experience subjective excessive daytime sleepiness and consequently observe no immediate benefit from using CPAP, which could contribute to poor long-term adherence. [27] [28] [29] Furthermore, our data suggest that a multidisciplinary approach to the treatment of OSA with the addition of exercise to CPAP therapy could have important health benefits.
We found that peak oxygen consumption and muscle performance improved significantly only in the exercise groups, but not with CPAP alone, even though CPAP was most effective in attenuating OSA severity. Because peak VO 2 is an independent predictor of survival 30 and crucial to the optimal timing of cardiac transplantation, 31 these findings have important clinical implications, even in patients who are adherent to CPAP.
It is noteworthy to emphasize that the results of the two CPAP arms of the present four-arm trial are consistent with the results of the two-arm (control vs CPAP) study of Mansfield et al. 32 In that study, patients with HFrEF and OSA were randomized to a CPAP group (n ¼ 19) and a control group (n ¼ 21). The duration of both trials and severity of OSA are similar. As in our study, Mansfield et al reported a lack of improvement in peak < .001
AHI ¼ apnea/hypopnea index; Arl ¼ arousal index; CAI ¼ central apnea index; CH ¼ central hypopneas; OAI ¼ obstructive apnea index; OH ¼ obstructive hypopneas; REM ¼ rapid eye movement; SaO 2 ¼ arterial oxygen saturation; TST ¼ total sleep time. a P < .05, baseline Â 3 months. P value from comparisons of mean difference (3 months -baseline) between groups: b P < .05 (CPAP or exercise þ CPAP vs control). c P < .05 (exercise or exercise and CPAP vs control). d P < .05 (exercise, CPAP, or exercise þ CPAP vs control).
chestjournal.org oxygen consumption, but improvements in both quality of life and Epworth Sleepiness Scale in the CPAP arm were noted. The major dissimilarity between the two studies is the heterogeneous causes of HF in the present study compared with the homogeneous cause of HF in the study by Mansfield et al.
Another finding of the present study relates to the incremental beneficial effects of exercise when combined with CPAP. Even though CPAP alone, compared with the baseline condition, improved quality of life, the magnitudes of improvement were largest in the exercise groups (Table 4) . Furthermore, a potentially important finding of this study is the improvement in sexual function noted only in the combination intervention. Although it should be noted that the overall P value (.053) was barely significant (potentially due to the small number of patients and multiple comparisons), when changes from baseline were considered, the combination group exhibited a significant beneficial effect, both in men and women (P ¼ .03). If confirmed by an independent larger study, this finding should be additional encouragement not only for exercise but also for CPAP adherence, which remains poor in general in patients with OSA, even in the presence of cardiovascular diseases. [33] [34] [35] In a study with a design similar to ours, Chirinos et al 36 randomized patients with moderate to severe OSA (without HF) to undergo a weight loss program, CPAP, and a combination of the two interventions. The authors found that those in the weight loss program only and those assigned to the combined interventions had reductions in C-reactive protein levels, insulin resistance, and serum triglyceride levels. None of these changes was observed in the group receiving CPAP alone. The results of that study P value from comparisons of mean difference (3 months -baseline) between groups: P < .05 (exercise and exercise þ CPAP vs control and CPAP). and the present one emphasize the importance of adjunctive therapy of OSA with weight loss and exercise when applicable. Given the poor long-term adherence to CPAP and the reluctance of some patients to use it at all, the results of these two studies are important in relation to the management of patients with OSA. It remains to be established if the combination of exercise and weight loss has a synergistic effect.
As noted earlier, a meta-analysis 9 reported that 3 to 6 months of exercise training reduced AHI by about 32% in adults with OSA without HF. The results of the present study (a 35% reduction in AHI) are consistent with those of the meta-analysis 9 and the study by Ueno et al 6 One important question is in respect to the mechanisms by which exercise may improve quality of life. Multiple molecular mechanisms are involved, 37, 39 and potential downstream reasons could be improved VE/VCO 2 slope and attenuation of exercise-induced oscillatory breathing. 40 These factors could collectively decrease the perception of dyspnea, allowing improvements in physical activity and the ability to perform daily chores.
The main limitation of the present study is the small number of patients enrolled and the short duration. However, longer duration studies may have ethical issues. Furthermore, 14 of the 70 study patients had Chagas disease, which is unique to Brazil. However, as discussed earlier, our results in the CPAP arm match those of Mansfield et al. 32 Among the 14 patients with Chagas disease, six happened to be in the control group and two to three in each therapeutic arm.
The strengths of the study include randomization, the inclusion of four study arms, the measurement of a relatively substantial number of variables, and the completion of relevant questionnaires by individuals blinded to randomization. Another noteworthy fact is that the exercise training was supervised, ensuring both adherence and quality.
Conclusions
In this prospective, four-arm, randomized controlled trial in patients with HFrEF and OSA, we observed that [33] [34] [35] showing that CPAP therapy had no effect on various OSA outcomes. However, we emphasize that the results of this preliminary study need to be confirmed by more definitive studies.
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